Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peng Yeh

Showing results (131-140 of 149) with videos related to

Pageof 15
Sort By:
Leukemia|March 24, 2020
Safety and efficacy of talacotuzumab plus decitabine or decitabine alone in patients with acute myeloid leukemia not eligible for chemotherapy: results from a multicenter, randomized, phase 2/3 studyPau Montesinos, Gail J Roboz, Claude-Eric Bulabois, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 25, 2016
Randomized, Double-Blind, Phase III Trial of Enzastaurin Versus Placebo in Patients Achieving Remission After First-Line Therapy for High-Risk Diffuse Large B-Cell LymphomaMichael Crump, Sirpa Leppä, Luis Fayad, et al.
Cancer Medicine|January 11, 2017
A targeted next-generation sequencing in the molecular risk stratification of adult acute myeloid leukemia: implications for clinical practicePo-Han Lin, Huei-Ying Li, Sheng-Chih Fan, et al.
Hemasphere|December 1, 2022
Distinct Immunogenetic Profiles of Chronic Lymphocytic Leukemia in Asia: A Taiwan Cooperative Oncology Group Registry StudyChi-Yuan Yao, Andreas Agathangelidis, Shih-Sung Chuang, et al.
American Journal of Hematology|February 12, 2024
Long-term follow-up of VIALE-A: Venetoclax and azacitidine in chemotherapy-ineligible untreated acute myeloid leukemiaKeith W Pratz, Brian A Jonas, Vinod Pullarkat, et al.
Hematological Oncology|October 17, 2022
A phase 1/2, open-label, multicenter study of isatuximab in combination with cemiplimab in patients with lymphomaCarmelo Carlo-Stella, Pier Luigi Zinzani, Anna Sureda, et al.
Blood Advances|June 5, 2023
Guadecitabine vs treatment choice in newly diagnosed acute myeloid leukemia: a global phase 3 randomized studyPierre Fenaux, Marco Gobbi, Patricia L Kropf, et al.
The Lancet. Haematology|December 22, 2015
Safety and tolerability of eltrombopag versus placebo for treatment of thrombocytopenia in patients with advanced myelodysplastic syndromes or acute myeloid leukaemia: a multicentre, randomised, placebo-controlled, double-blind, phase 1/2 trialUwe Platzbecker, Raymond S M Wong, Amit Verma, et al.
Blood|May 4, 2022
Prospective comparison of outcomes with azacitidine and decitabine in patients with AML ineligible for intensive chemotherapyAmer M Zeidan, Pierre Fenaux, Marco Gobbi, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|August 9, 2019
Recombinant Zoster Vaccine Significantly Reduces the Impact on Quality of Life Caused by Herpes Zoster in Adult Autologous Hematopoietic Stem Cell Transplant Recipients: A Randomized Placebo-Controlled Trial (ZOE-HSCT)Desmond Curran, Sean Matthews, Scott D Rowley, et al.
Pageof 15

Showing results (131-140 of 149) with videos related to

Sort By:
Pageof 15
Leukemia|March 24, 2020
Safety and efficacy of talacotuzumab plus decitabine or decitabine alone in patients with acute myeloid leukemia not eligible for chemotherapy: results from a multicenter, randomized, phase 2/3 studyPau Montesinos, Gail J Roboz, Claude-Eric Bulabois, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 25, 2016
Randomized, Double-Blind, Phase III Trial of Enzastaurin Versus Placebo in Patients Achieving Remission After First-Line Therapy for High-Risk Diffuse Large B-Cell LymphomaMichael Crump, Sirpa Leppä, Luis Fayad, et al.
Cancer Medicine|January 11, 2017
A targeted next-generation sequencing in the molecular risk stratification of adult acute myeloid leukemia: implications for clinical practicePo-Han Lin, Huei-Ying Li, Sheng-Chih Fan, et al.
Hemasphere|December 1, 2022
Distinct Immunogenetic Profiles of Chronic Lymphocytic Leukemia in Asia: A Taiwan Cooperative Oncology Group Registry StudyChi-Yuan Yao, Andreas Agathangelidis, Shih-Sung Chuang, et al.
American Journal of Hematology|February 12, 2024
Long-term follow-up of VIALE-A: Venetoclax and azacitidine in chemotherapy-ineligible untreated acute myeloid leukemiaKeith W Pratz, Brian A Jonas, Vinod Pullarkat, et al.
Hematological Oncology|October 17, 2022
A phase 1/2, open-label, multicenter study of isatuximab in combination with cemiplimab in patients with lymphomaCarmelo Carlo-Stella, Pier Luigi Zinzani, Anna Sureda, et al.
Blood Advances|June 5, 2023
Guadecitabine vs treatment choice in newly diagnosed acute myeloid leukemia: a global phase 3 randomized studyPierre Fenaux, Marco Gobbi, Patricia L Kropf, et al.
The Lancet. Haematology|December 22, 2015
Safety and tolerability of eltrombopag versus placebo for treatment of thrombocytopenia in patients with advanced myelodysplastic syndromes or acute myeloid leukaemia: a multicentre, randomised, placebo-controlled, double-blind, phase 1/2 trialUwe Platzbecker, Raymond S M Wong, Amit Verma, et al.
Blood|May 4, 2022
Prospective comparison of outcomes with azacitidine and decitabine in patients with AML ineligible for intensive chemotherapyAmer M Zeidan, Pierre Fenaux, Marco Gobbi, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|August 9, 2019
Recombinant Zoster Vaccine Significantly Reduces the Impact on Quality of Life Caused by Herpes Zoster in Adult Autologous Hematopoietic Stem Cell Transplant Recipients: A Randomized Placebo-Controlled Trial (ZOE-HSCT)Desmond Curran, Sean Matthews, Scott D Rowley, et al.
Pageof 15